Compare Hims and Hers Health Inc (HIMS) vs JD.Com Inc (JD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hims and Hers Health Inc vs JD.Com Inc — how do they compare? Hims and Hers Health Inc trades at $28.41 (market cap $6.89B), while JD.Com Inc trades at $26.98 (market cap $36.51B). The key difference: JD.Com Inc is far larger — about 5.3× Hims and Hers Health Inc's market cap, and JD.Com Inc pays a 3.7% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hims and Hers Health Inc for 21 Days and JD.Com Inc for 85 Days on average.
| HIMS | JD | |
|---|---|---|
Market Cap | $6.89B | $36.51B |
Volume | 5,446,628 | 7,051,146 |
Sector | Health | Consumer Cyclical |
52-Week High | $62.76 | $34.53 |
52-Week Low | $14.52 | $25.19 |
Typical Hold Time | 21 Days | 85 Days |
Enterprise Value | $7.60B | $19.16B |
Dividend Yield | — | 3.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hims & Hers Health trades at $29.54, up 0.24% on the day, with a bullish technical signal from moving averages but mixed earnings performance. Revenue grew to $2.35 billion in 2025, yet the company posted a net loss of $142 million in 2026, reflecting profitability challenges. High valuation ratios like a P/E of 57.14 and negative ROE of -32.03% indicate premium pricing despite weak earnings. Recent news highlights multiple securities class action lawsuits filed in October 2026, creating legal overhangs.
The stock faces headwinds from profitability struggles and legal risks, but analyst consensus remains a Buy with a $32.17 price target, suggesting modest upside. Investment appeal hinges on resolving operational inefficiencies and legal issues to align valuation with fundamentals, while current sentiment is cautious due to recent earnings misses and regulatory scrutiny.
JD.com trades at $26.91, up 1.55% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $0.93 surpassing the $0.86 estimate. The company maintains robust fundamentals, including a low P/S ratio of 0.2 and a solid cash position of $234 billion as of 2024. Positive developments include potential EU approval for the $2.5 billion Ceconomy acquisition, signaling strategic expansion.
The outlook for JD.com is positive, supported by undervaluation metrics and strong free cash flow, though risks include revenue declines and regulatory scrutiny. With 69.57% of analysts rating it a Buy and a consensus price target of $35.86, the stock offers significant upside potential, but investors should monitor competitive pressures and macroeconomic headwinds in the Chinese market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →About JD.Com Inc
JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
Read more on JD →
